header logo image


Page 293«..1020..292293294295..300310..»

Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

November 22nd, 2020 11:56 am

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the launch of a dedicated website for its affiliate Altamira Medica Ltd. The website, www.altamiramedica.com, offers quick and easy access to information about the Company’s development of AM-301, a drug-free nasal spray intended for self-protection against risks from exposure to airborne viruses and allergens.

View post:
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica

Read More...

Chalice Farms to Launch “Holiday in Color” Pre-Roll Packs, Festive Promotions through Holiday Season

November 22nd, 2020 11:56 am

PORTLAND, Ore., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE:GLH) (OTCQB:GLDFF) (“Golden Leaf” or the “Company”), a premier, consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, announces that Chalice Farms, a wholly owned subsidiary of Golden Leaf, will spread holiday cheer by launching a “Holiday in Color” pre-roll pack, along with weekly promotions and specials through the holidays, available now.

Continued here:
Chalice Farms to Launch “Holiday in Color” Pre-Roll Packs, Festive Promotions through Holiday Season

Read More...

LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering

November 22nd, 2020 11:56 am

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering of 7,500,000 shares at $10.00 per share. The shares will begin trading today on the NASDAQ Capital Market (“NASDAQ”) under the symbol “LSAQ.”

View original post here:
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering

Read More...

Zenith Files Notice of Annual and Special Meeting of Shareholders

November 22nd, 2020 11:56 am

CALGARY, Alberta, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) today announces the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the “Notice”) related to its Annual and Special Meeting of Shareholders (the “Meeting”) being held on Tuesday, December 22, 2020 commencing at approximately 2:00 pm (MT).

Originally posted here:
Zenith Files Notice of Annual and Special Meeting of Shareholders

Read More...

Resverlogix Files Notice of Annual and Special Meeting of Shareholders

November 22nd, 2020 11:56 am

CALGARY, Alberta, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the “Notice”) related to its Annual and Special Meeting of Shareholders (the “Meeting”) being held on Tuesday, December 22, 2020 commencing at approximately 1:00 pm (MT).

Read the original post:
Resverlogix Files Notice of Annual and Special Meeting of Shareholders

Read More...

Study suggests link between type 2 diabetes and cardiovascular risk – Medical News Today

November 22nd, 2020 11:56 am

Researchers have identified a link between type 2 diabetes and cardiovascular health issues even in people with optimally controlled cardiovascular risk factors.

In a new study, scientists have discovered a link between type 2 diabetes and an increased risk of cardiovascular issues, even for people who optimally control the common risk factors for cardiovascular disease.

The research, which appears in the journal Circulation, suggests that early treatment of people with type 2 diabetes for cardiovascular disease may significantly reduce cardiovascular events and mortality.

According to the Centers for Disease Control and Prevention (CDC), 1 in 10 people in the United States have diabetes, and of those, 9095% have type 2 diabetes.

The cells of a person with type 2 diabetes do not react to insulin in the way they should. A persons pancreas produces insulin, which enables the sugar carried by the bloodstream to enter the cells of the body.

Because blood sugar is not being removed from a persons bloodstream, their blood sugar levels can increase to dangerous levels. According to the CDC, this can cause vision loss, kidney disease, and heart disease.

Researchers have shown that having type 2 diabetes increases a persons risk of developing both non-fatal and fatal forms of cardiovascular disease.

Studies also state that people with type 2 diabetes who optimally control common cardiovascular risk factors can reduce their chances of developing cardiovascular events. The authors of the new Circulation study cite research showing that this may prolong a persons life by up to 8 years.

According to the CDC, risk factors for cardiovascular disease include high blood pressure, high cholesterol, smoking, obesity, an unhealthy diet, low physical activity, and diabetes.

Researchers suggest that people who optimally manage their cardiovascular risk factors could completely negate the associated risk between type 2 diabetes and cardiovascular disease.

In the present article, the researchers wanted to see if this latter studys findings, conducted with a Swedish population, were reproducible in a population from the United Kingdom.

According to Dr. Alison Wright, first author of the study and research associate at the Centre for Pharmacoepidemiology and Drug Safety at the University of Manchester, U.K., [p]revious studies have shown that people with type 2 diabetes had little or no excess risk of cardiovascular disease events or death when all risk factors are optimally controlled.

Our team sought to determine how the degree of risk factor control in people with type 2 diabetes impacted cardiovascular disease risk and mortality, compared to people with type 2 diabetes who had all risk factors optimally controlled and to people who do not have type 2 diabetes.

To go about this, the researchers looked at clinical data gathered during 20062015. The data included over 101,000 people with type 2 diabetes. The team matched these with another group of almost 331,000 people with type 2 diabetes, as well as a group of nearly 379,000 without type 2 diabetes.

Following U.K. clinical guidelines, the researchers looked at five cardiovascular risk factors: cholesterol, triglycerides, smoking, blood glucose, and blood pressure.

They looked particularly at the association between optimally controlling these risk factors and cardiovascular events or mortality in people with type 2 diabetes, compared with people who did not have the condition.

The researchers found that even when optimally controlling the five risk factors for cardiovascular issues, people with type 2 diabetes still had a 21% increased risk of developing cardiovascular disease compared with those without type 2 diabetes.

They also had a 31% increased risk of hospitalization due to heart failure.

For Dr. Wright, the findings suggest that early intervention in cardiovascular risk for people with type 2 diabetes is important:

People with type 2 diabetes should be treated for cardiovascular risk factors as early as possible, regardless of whether they have cardiovascular disease or not.

There is real potential here to reduce the overall impact of type 2 diabetes on future cardiovascular events, especially for patients with type 2 diabetes who have not yet been diagnosed with cardiovascular disease.

The researchers also discovered that people with type 2 diabetes tended to have poor management of cardiovascular risk factors, which scientists note is an international issue, following recent research.

In the present study, only 6% of the participants with type 2 diabetes were optimally managing their risk factors.

As a consequence, Dr. Wright and her co-authors also suggest that [g]reater use of guideline-driven care, clinical decision support, drug intervention, and self-management support should be encouraged.

Continued here:
Study suggests link between type 2 diabetes and cardiovascular risk - Medical News Today

Read More...

The impact of diabetes in South Carolina – WLTX.com

November 22nd, 2020 11:56 am

Diabetes is the seventh leading cause of death in South Carolina, according to health officials.

COLUMBIA, S.C. Diabetes is the seventh leading cause of death in South Carolina and over half a million South Carolinians are estimated to have diabetes, according to the latest data from the S.C. Department of Health and Environmental Control (DHEC).

"I tell my patients all the time, diabetes is a disease of the diet," said Dr. Jaqui Jones with Prisma Health. She suggests limiting processed foods, exercising, and eating healthier foods, like vegetables and lean meats to avoid type two diabetes.

"I have diagnosed patients in my clinic as young as 21, 22 years old, which is so young. Its too young to have type 2 diabetes, but it is happening," Jones said.

Diabetes is especially prevalent in South Carolina.

In 2018, the Palmetto State ranked 8th in diabetes deaths in the nation, according to DHEC. Over 1,500 South Carolinians died from the disease that year.

The Centers for Disease Control and Prevention (CDC) says someone with diabetes is more likely to have a severe case of COVID-19.

"[if you have diabetes] youre already chronically inflamed, youre already at risk of other things, your immune system is not as optimal as we want it to be. So, something that comes along like COVID, which is already hard and new to treat, you have an increased risk of poor outcome," Dr. Jones explained.

This year, BlueCross BlueShield of South Carolina started an initiative called Diabetes Free SC, which is dedicated to improving health outcomes for people in South Carolina who have diabetes.

Dr. Timothy Lyons, director of the initiative, said, "its not something which is directed at insured lives of BlueCross, its for a whole population of South Carolina with a big emphasis on people who are disadvantaged and people who live in underserved rural areas and of course health disparities."

Dr. Lyons said they fund programs that help reduce the risks of diabetes in children, pregnant women and adults. Theyve invested nearly 12 million dollars so far in diabetes prevention.

If someone is at risk for diabetes, Dr. Jones says the first step is to go to the doctor and get tested.

Go here to see the original:
The impact of diabetes in South Carolina - WLTX.com

Read More...

93% of patients with type 2 diabetes are at an increased risk of a fatal heart attack or stroke – Cardiovascular Business

November 22nd, 2020 11:56 am

A whopping 93% of adult patients with type 2 diabetes (T2D)are at a high risk of experiencing a fatal acute myocardial infarction (AMI) or stroke, according to new research published in the European Journal of Preventive Cardiology.

The study was focused on data out of Catalonia, Spain, but its findings will likely still grab the attention of researchersand patientsall over the world.

Traditionally, cardiovascular risk in the region has been lower than in central and northern Europe or the U.S., co-author Manel Mata-Cases, PhD, of the Catalan Institute of Health in Barcelona, Spain, said in a statement. Therefore, our results should generate concern and a call for action to prevent heart attacks and strokes in people with T2D managed in primary care.

Mata-Cases et al. explored data from nearly 374,000 adult patients in Catalonia. Each patient had a confirmed diagnosis of type 2 diabetes as of Dec. 31, 2016. The average age was 70.1 years old. Each patients risk was determined by identifying such factors as a history of cardiovascular disease, high blood pressure and obesity.

Follow this link:
93% of patients with type 2 diabetes are at an increased risk of a fatal heart attack or stroke - Cardiovascular Business

Read More...

Diabetes drug shows promise in treating and reversing heart failure – Medical News Today

November 22nd, 2020 11:56 am

A newly released study found that people with heart failure who received the diabetes drug empagliflozin showed significant improvements in heart structure and function, with many experiencing a reversal of the disease.

Approximately 6.2 million adults in the United States have heart failure. As a result of its high prevalence, the national cost of healthcare services, medicines, and missed workdays related to this disorder reached an estimated $30.7 billion in 2012.

Globally, the disease affects approximately 23 million people.

Heart failure occurs when the heart cannot pump blood effectively to other parts of the body, causing symptoms that include shortness of breath, difficulty breathing, weakness and tiredness, and weight gain and swelling in the legs, ankles, feet, or stomach.

It may progress to congestive heart failure due to the buildup of fluids in the lungs, liver, and lower extremities.

Underlying causes of heart failure include coronary artery disease, high blood pressure, obesity, heart valve disease, and diabetes. Over time, these diseases may result in adverse modeling, which is the hearts attempt to compensate for its added workload by getting larger, developing thicker walls, and pumping more frequently.

Among people with heart failure, about 50% present with heart failure with reduced ejection fraction (HFrEF). The lowered ejection fraction occurs when the hearts left ventricle cannot pump blood effectively, decreasing the amount of blood that leaves the ventricle to circulate the body after each contraction.

Treatment options for heart failure include taking prescription drugs, reducing the amount of sodium in the diet, consuming a lower volume of liquids, and making any necessary lifestyle changes, such as reaching a moderate weight, quitting smoking, and eating a heart-healthy diet.

With limited heart failure treatment options available, researchers from the Icahn School of Medicine at Mount Sinai set up a clinical trial called EMPATROPISM to investigate the use of empagliflozin, a diabetes drug, for treating HFrEF in people without diabetes.

The researchers presented the trial results on November 13 at the American Heart Association (AHA) Scientific Sessions 2020, with a pre-proof appearing in the Journal of the American College of Cardiology.

In the double-blind, placebo-controlled, randomized study, the scientists divided the 84 participants, who were 1885 years of age, into two groups. One group received 10 milligrams (mg) of empagliflozin daily, and the other took a placebo.

At the trials onset, all of the participants underwent baseline evaluations, which included cardiac MRI, a 6-minute walk test, and a cardiopulmonary exercise test to determine their oxygen levels. They also completed questionnaires regarding their quality of life.

After 6 months of receiving either the placebo or empagliflozin, the participants completed the same tests again.

The researchers found that approximately 80% of those who received the medication showed significant improvement in their condition, with a 16.6% improvement in left ventricle ejection fraction.

They also experienced a reduction in heart size and thickness and had less congestion, indicating that their heart failure had become less severe.

Remarkably, the investigators note that the heart returned to near normal in this group of participants.

Additionally, those who received empagliflozin experienced no severe side effects and saw improvements in their exercise levels and quality of life, which occurred relatively quickly after beginning the medication.

Although empagliflozin is an antidiabetes drug, the investigators noted no adverse blood sugar-related side effects, such as hypoglycemia, in the study participants, despite them not having diabetes.

Conversely, the study participants who took the placebo showed no improvements. Their condition either stayed the same or worsened, with a further reduced ejection fraction, increased heart size and thickness, and an abnormal change in the hearts overall shape.

According to the researchers, the study results also explain why this medication effectively treats heart failure. They explain that it essentially reverses the adverse modeling that occurs when the heart attempts to restructure itself to compensate for changes associated with other chronic conditions.

The EMPEROR-Reduced trial, a slightly earlier study that featured in the New England Journal of Medicine, saw similar results. In this double-blind trial, 3,730 people with HFrEF took either empagliflozin (10 mg once daily) or a placebo, in addition to recommended therapy.

The results concurred with the EMPATROPISM findings, showing that people both with and without diabetes in the empagliflozin group experienced a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group.

The EMPATROPISM studys first author, Carlos Santos-Gallego, a postdoctoral fellow at the Icahn School of Medicine, explains the implications of these findings.

He says, Our clinical trials promising results show this diabetes drug can ameliorate lives of heart failure patients with reduced ejection fraction, enhance their exercise capacity, and improve their quality of life with little to no side effects.

We expect this work will help lead to U.S. Food and Drug Administration [FDA] approval of empagliflozin for this patient population in the coming months.

The rest is here:
Diabetes drug shows promise in treating and reversing heart failure - Medical News Today

Read More...

Know the risks: November is National Diabetes Awareness Month – Bangor Daily News

November 22nd, 2020 11:56 am

BANGOR November is National Diabetes Awareness Month and a time for all Bangor region residents to assess their risk for developing prediabetes or type 2 diabetes. Currently, of the 88 million adults with prediabetes only 20 percent know they have the condition. In addition to the high risk of developing type 2 diabetes, people with prediabetes are also at risk of developing other chronic diseases such as heart disease and stroke.

Prediabetes is a condition in which a persons blood glucose is elevated, but not high enough for a diabetes diagnosis. To address this issue, The Bangor Region YMCA will be introducing the YMCAs Diabetes Prevention Program to the region in January, which will help adults lose weight through healthier eating and increased physical activity, potentially preventing or delaying the onset of type 2 diabetes.

The YMCAs Diabetes Prevention Program is a group-based lifestyle intervention for adults who are prediabetic and at high-risk of developing type 2 diabetes. This program has been shown to reduce the number of new cases of diabetes by 58 percent overall and by 71 percent in adults over 60.

At the Y, we take a community integrated approach to improving health, meaning we move health care out of the clinic and into the community where people can more easily access the care they need, said Diane Dickerson, CEO of The Bangor Region YMCA. Currently much of our focus is on prevention programs like the YMCAs Diabetes Prevention Program that provides a safe and supportive environment where people can learn to change behaviors and potentially decrease chances of developing type 2 diabetes.

Individuals can assess their risk for prediabetes and type 2 diabetes by taking a simple test at YMCA.net/diabetes. Through this assessment, visitors can also learn how lifestyle choices and family history help determine the ultimate risk for developing the disease. Several factors that could put a person at risk for type 2 diabetes include family history, race, age, weight and activity level. If a person is at risk, a diabetes screening conducted by a physician can confirm a diabetes or prediabetes diagnosis.

The YMCAs Diabetes Prevention Program, part of the Centers for Disease Control and Prevention (CDC) led National Diabetes Prevention Program, is a 12-month evidence-based program for those who are prediabetic that features a lifestyle coach who helps participants learn tactics for healthy eating, physical activity and other lifestyle changes during 25, one-hour classroom sessions. Long-term program goals include reducing participants body weight by 5 to 7 percent and increasing physical activity to 150 minutes per week. Nationally, more than 68,000 people participated in the program at almost 1,100 sites in 40 states throughout the country. Participants who completed the yearlong program lost an average of 5.5 percent of body weight and completed an average of 168 minutes of physical activity per week.

For more information about how to qualify for access to the upcoming YMCAs Diabetes Prevention Program at The Bangor Region YMCA, contact Jennifer Crane, healthy living programs manager, at jcrane@bangorY.org.

Read the original here:
Know the risks: November is National Diabetes Awareness Month - Bangor Daily News

Read More...

Mee Memorials drive-thru educational event brings awareness to diabetes – King City Rustler

November 22nd, 2020 11:56 am

KING CITY Mee Memorial Healthcare System observed Diabetes Awareness Month and World Diabetes Day with a Nov. 12 drive-thru educational event.

Attendees were able to pull through the hospital parking lot in King City and pick up diabetes information, which included a risk-assessment questionnaire.

Heidi Pattison, Mee Memorials director of outpatient clinics, said an estimated 45% of residents in Monterey County are prediabetic.

We have some providers in the clinic where up to 80% of their patients are diabetic or prediabetic, Pattison said. Its crucial to get the word out about warning signs, eating properly and behaviors they can change.

The drive-thru format was a first for the event, which staff said would typically be run with more of a health fair format, if not for health concerns due to Covid-19. Staff were able to not only provide materials to attendees, but also explain the information contained within for those with questions.

People who have diabetes are at higher risk of severe coronavirus infection, said Dr. Joshua Deutsch, a family practice provider with Mee Memorial.

Deutsch added that South Monterey County has a higher percentage of people with diabetes and a higher percentage of obesity than the overall county.

Access to care is poorer here, so people with diabetes are more likely to have uncontrolled diabetes or to have some of the complications of diabetes neglected, so it becomes a more severe disease burden, he said.

The diabetes event came as part of Mee Memorials interest in being more active in the community, part of a goal of the new administration, Deutsch said.

To be more active and address more of the communitys needs, he said. It is challenging with coronavirus to have an active community presence and to go out and meet people.

In order to address more of the community and their health issues, Deutsch said it takes meeting people halfway and in public. That allows reaching people who might be afraid or havent thought of meeting with a physician in a clinic.

The overall campaign is designed to get the publics attention, to motivate people to action and to encourage community members to get further education or see their physician.

Excerpt from:
Mee Memorials drive-thru educational event brings awareness to diabetes - King City Rustler

Read More...

Diabetes Diet: This Winter Salad Made With Carrots And Paneer Is A Soul-Soothing Treat – NDTV Food

November 22nd, 2020 11:56 am

Highlights

Afflicting millions across home and abroad, diabetes is a condition marked by fluctuating blood sugar levels. Unfortunately, there is no known cure for diabetes. The condition cannot be reversed but can be managed to a great extent. Diabetics need to be extra cautious about their diet, lifestyle and medicines. With the festive season upon us, most of us are left with a trail of mithai ka dabbas and snacks that need to be consumed well within their shelf life. Then there are the mid-meal cravings that steer you towards the unhealthiest of snacks. It is important to sort your priorities. If you happen to be a diabetic, you know you cannot really gorge on sweets like other people with blessed metabolism. So, what do you do? Think about healthier options, perhaps?

(Also Read:Carrot Nutrition: Benefits Of Carrot, Nutrition Chart And More)

Winter season is renowned for many fruits and vegetables that could help keep your blood sugar levels in control. Carrots, guavas, radish, beetroot, methi, sarso are just some of the winter superfoods that you can include in your diet. You can tuck into them raw, blend them in smoothies, use them in soups, make healthy curries out of it, or make a quick and yummy salad. Yes, you heard us. A 'yummy' salad is no paradox. If you are willing to experiment, salads need not be the same old banal and boring affair.

(Also Read:11 Best Paneer Recipes | Easy Paneer Recipes | Popular Cottage Cheese Recipes)

Salads often have enough room for creativity, so put those thinking caps on and think about all high-fibre, seasonal treats you can add to your salads. Fibre helps the slow release of sugar in the bloodstream, preventing abrupt blood sugar spikes. Here's one recipe we have tried recently that you catch your fancy.

Low-Carb Diet: Add carrots to your diet for a healthy boost

Winter Salad For Diabetes:

Ingredients:

Promoted

Method:1. Take a big mixing bowl and add onions, carrots, tomatoes.2. Now add the paneer, black pepper powder, lemon juice and coriander.3. Mix everything well. Ad chomp away.

Try making this salad at home. Add or remove elements according to your preferences. It is your salad after all!

(This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.)

About Sushmita SenguptaSharing a strong penchant for food, Sushmita loves all things good, cheesy and greasy. Her other favourite pastime activities other than discussing food includes, reading, watching movies and binge-watching TV shows.

See the article here:
Diabetes Diet: This Winter Salad Made With Carrots And Paneer Is A Soul-Soothing Treat - NDTV Food

Read More...

Abbott Becomes First Anchor Sponsor of American Diabetes Association’s Health Equity Now Initiative to Advance Access to Care and Technology for…

November 22nd, 2020 11:56 am

ABBOTT PARK, Ill. and ARLINGTON, Va., Nov. 18, 2020 /PRNewswire/ --Today, Abbott (NYSE: ABT) and the American Diabetes Association (ADA) announced that Abbott has become the first anchor sponsor of the Health Equity Now(HEN) platform to address health disparities for people with diabetes. Abbott's sponsorship includes a three-year, $5 million commitment to support the ADA's advocacy and community-driven projects aimed at removing barriers to care and providing greater access to the latest medical technologies and health resources for underserved diabetes populations.

"It's important that people with diabetes in the U.S. have access to the latest innovations to effectively manage their condition and help them thrive," said Tracey D. Brown, chief executive officer of the American Diabetes Association. "It is time to tear down the systemic barriers that separate us based on zip code, income level, education, color and gender, and it's time that we demand health equity now."

Data show that compared to white adults, the risk of being diagnosed with diabetes is higher among Black Americans (77%), Latinos (66%), and Asian Americans (18%).1 With 50% of low-income Americans with diabetes having lost some or all income during the pandemic,2 COVID-19 has brought greater attention to the large gaps in the U.S. healthcare system, shining a light on the health and economic disparities faced by Americans in underserved communities.

To address these health inequities, the ADA created the Health Equity Bill of Rights, which includes a core right for all to access the latest medical advances. Abbott will support the ADA's advocacy efforts to tear down barriers that limit access to high-quality medical technologies, including continuous glucose monitoring (CGM) advancements, among others.

"No matter someone's race, income level or background, quality care and life-changing technologies should be affordable and broadly accessible to all people living with diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "Abbott is proud to support the ADA's goal to work toward health equity and to advance access to the latest technologies for people with diabetes, helping them lead healthier, fuller lives with dignity."

Another primary focus of Abbott's sponsorship will drive sustained community engagement through local programs and initiatives to help improve diabetes-related health outcomes. With Abbott's support, the ADA will immediately begin work to bring together experts and collaborate with underserved communities to develop key program outreach models that include public health education, professional education and training and other community services that will be rolled out in 2021.

About the American Diabetes Association:Every day more than 4,000 people are newly diagnosed with diabetes in America. More than 122 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 80 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us atdiabetes.orgor call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook(American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).

About Abbott:As part of our purpose to help people live fuller lives through better health, Abbott is committed to advancing health equity, working side-by-side with the communities we serve to address health disparities and tackle barriers to health. This includes efforts across our business and in partnership with others to expand access to technology, quality care and nutrition, and to advance STEM and health education to inspire a diverse and innovative next generation. Looking ahead, Abbott will further extend these efforts with the launch of its 2030 sustainability strategy and plan later this year, with forward-looking targets to build a stronger, more sustainable Abbott that better serves the many people who depend on us. To learn more about Abbott's strategic approach to sustainability, please visit abbott.com/sustainability.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at http://www.abbott.com, on LinkedIn at http://www.linkedin.com/company/abbott-/, on Facebook at http://www.facebook.com/Abbott and on Twitter @AbbottNews.

1Ying-Ying Meng et al. Racial and Ethnic Disparities in Diabetes Care and Impact of Vendor-Based Disease Management Programs. Diabetes Care, May 2016.2Diabetes and COVID-19: New Data Quantifies Extraordinary Challenges Faced by Americans with Diabetes During Pandemic. Survey by dQ&A and The American Diabetes Association. July 2020.

View original content:http://www.prnewswire.com/news-releases/abbott-becomes-first-anchor-sponsor-of-american-diabetes-associations-health-equity-now-initiative-to-advance-access-to-care-and-technology-for-people-with-diabetes-301175816.html

SOURCE Abbott

See the rest here:
Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for...

Read More...

Early intervention key in treating diabetic eye disease – KTBS

November 22nd, 2020 11:56 am

TEXARKANA, Texas -- This month's emphasis on Diabetic Eye Disease Awareness gives healthcare workers the chance to spread the wordabout how people with diabetes can protect theirvision.

People with diabetes are more likely to develop eye diseases that lead to blindness. Diabetic retinopathy is the most common cause of vision impairment or blindness in working-age adults.

Dr. Roshan George, a retina surgeon at Collum and Carney Clinic in Texarkana, says the condition is caused by damage to blood vessels in the eyes.

So, when you have diabetes in the eyes, it starts decreasing the blood circulation. And as a result your body can create new and abnormal vessels, which bleed, George explains. Sometimes the bleeding can turn into scar tissue formation. And ultimately, those lead to blindness.

Diabetes can also cause macular edema, which is a build-up of fluid in the retina. George says early intervention can help many people who are losing their eyesight due to diabetes.

So there are definitely plenty of patients, even when theyve had diabetic retinopathy, as long as we address it early, address it effectively, those patients actually do very well.

Both conditions can be treated with injections and laser surgery. Early intervention can make all the difference.

Read more:
Early intervention key in treating diabetic eye disease - KTBS

Read More...

UPDATED: Vivek Ramaswamy’s Metavant hits a brick wall, abandoning a lead program for diabetes. And there’s nothing visible left to see here -…

November 22nd, 2020 11:56 am

Just a few years after Vivek Ramaswamys epic Alzheimers fail, another one of his startups is cutting its losses because of a high-risk endeavor this time on the diabetes front didnt pan out.

Metavant, Ramaswamys biotech #7, has decided not to advance its lead candidate imeglimin into Phase III, instead of looking for a quick sell-off. If it doesnt secure a deal within 60 days, the rights go back to Merck KGaA spinout Poxel, which licensed the drug to Roivant the parent company to Ramaswamys suite of vants back in 2018 for $50 million in cash and up to $600 million in milestones.

A spokesperson for Metavant tells Endpoints News there are currently no disclosed drugs in the pipeline, and didnt rule out that possibility. But for now, barring some stealth programs or deals in the works, the company looks dormant.

Poxel says Metavants decision wasnt based on efficacy, safety, or other data. We conducted an internal review and determined that advancing imeglimin was not strategically appropriate for us, Metavant said in a short email statement to Endpoints.

In a separate partnership with Sumitomo Dainippon Pharma, the drug successfully completed a Phase III program and is currently under regulatory review for Type 2 diabetes in Japan. Poxel CEO Thomas Kuhn said the drug could hit the market next year, adding that the company is fully committed to future development and commercialization.

Todays announcement does not impact the agreement for Imeglimin with Sumitomo Dainippon Pharma. Moving forward, we are preparing to explore various options to advance Imeglimin into a Phase 3 development program in the US, Europe and other countries currently covered under the Metavant agreement, Kuhn said in a statement.

Metavants only other program was a diabetes drug licensed from Ligand, for which it returned the rights earlier this year. Roivant paid $20 million in cash and promised up to $513.8 million in milestones for the glycogen receptor inhibitor, called LGD-6972.

In its Q2 2019 financial report, Ligand said continued development of the program was highly unlikely due to changes in FDA requirements.

Metavant has been working with FDA to determine a path forward for the glucagon receptor antagonist or GRA program now known as RVT-1502 in diabetes. Ligand believes that continued development of RVT-1502 for diabetes in the U.S. is highly unlikely based on preclinical and clinical trials now required by FDA for any drug in the GRA class intended for long-term use. Metavant may choose to explore certain other indications and/or geographies for RVT-1502 and expects to make a decision later this year.

Earlier this month, Ramaswamys Axovant changed its name to Sio Gene Therapies in a complete rebrand, marking its three-year shift away from Alzheimers disease. Were not a vant any longer, CEO Pavan Cheruvu said, adding that Roivant is no longer a majority stakeholder.

The implosion of the Metavant deal underscores just how rare it is for a biotech company to attempt to try anything on the diabetes front, a field dominated by a handful of giant players that can afford to cover the immense cost of huge late-stage studies often in pursuit of marginal medical gains for patients. And with this latest failure, its even less likely well see more in small companies anytime soon.

Read more here:
UPDATED: Vivek Ramaswamy's Metavant hits a brick wall, abandoning a lead program for diabetes. And there's nothing visible left to see here -...

Read More...

Gut health: How to improve yours and help fight diabetes – KSL.com

November 22nd, 2020 11:56 am

SALT LAKE CITY November is National Diabetes Month, a month when Americans across the country join together to bring awareness to diabetes.

Learning more about diabetes, its risk factors and treatments is key to prevention, as well as improving outcomes. The American Diabetes Association lists many risk factors for diabetes such as diet, lifestyle, genetics and environment but what about your gut health? Let's look at what the research says, plus learn how you can improve your gut health.

Gut health refers to how well your gut performs the various aspects of digestion. From that first bite of food to emptying your bowels, and everything in between, digestion encompasses simple processes, such as chewing, as well as other more complex processes.

When talking about gut health, you'll often hear the term "gut microbiome." This simply refers to the trillions of microorganisms and bacteria that call your gut home. These beneficial bacteria help your body with many different functions, including digestion and absorption of nutrients, supporting your body's immune system, protection against pathogens you may have consumed, making vitamins and other compounds, and eliminating waste products.

Studies, like this 2019 study out of South Korea, have shown when the number of bad bacteria outweighs the number of good bacteria in your gut, these intricate processes suffer. Oftentimes inflammation is introduced, followed by a number of possible health problems.

Prebiotics are components of nondigestible fibers (a carbohydrate) found naturally in many plant-based foods, including fruits, vegetables and whole grains. Sometimes they are also added to processed foods.

Prebiotics pass through the digestive system without being digested. As they move through your digestive tract they promote the growth and activity of "good" bacteria. In a nutshell, they are the food for probiotics.

Probiotics are the "friendly" or "good" bacteria in your digestive system. These are live bacterial cultures found in certain foods or supplements, such as yogurt with live cultures, aged cheeses and fermented foods. They live in your gut and perform specific functions, as mentioned previously, to help keep your gut healthy and functioning properly.

Additionally, some of your gut bacteria form vitamin K and short-chain fatty acids. Short-chain fatty acids are the main source of nutrition for the cells that line the colon. They build a strong gut barrier that helps keep out harmful bacteria, viruses and other substances. Research published by MDPI in 2011 shows this process also reduces inflammation, and a 2020 article in the journal Current Medicinal Chemistry says it may reduce the risk of colon cancer.

When there is a lack of beneficial bacteria in the gut, there is less fermentation of dietary fiber, resulting in decreased short-chain fatty acid production. A 2018 study published in the March issue of Science magazine examined the link between short-chain fatty acid production and Type 2 diabetes. Chinese researchers randomized patients with Type 2 diabetes to receive either traditional patient education and dietary recommendations (control group) or a high-fiber diet composed of whole grains, traditional Chinese medicinal foods, and prebiotics (test group).

Researchers found that in the high-fiber test group there were more bacteria that produced short-chain fatty acid through fiber digestion, resulting in better improvement in blood glucose levels when compared to the control group. These results suggest that reduction in short-chain fatty acids in the gut may be associated with Type 2 diabetes.

Additionally, 2017 research from the Finnish Diabetes Prevention Study found that people who had more fiber in their diets had more anti-inflammatory markers in their blood made by gut bacteria. They also had a lower risk of developing Type 2 diabetes.

While these findings suggest possible links between gut health and diabetes, there is still much research to be done in this area. More large, high-quality studies are needed to determine how and why diabetes is affected by the gut microbiome.

1. Eat a healthy, varied diet

It really is true that you are what you eat, or at least your gut health is what you eat. Consuming a variety of prebiotic- and probiotic-rich foods will help your gut bacteria thrive, allowing them to better perform their daily digestive functions.

Prebiotics are found naturally in many plant-based foods, including asparagus, chicory root, garlic, Jerusalem artichokes, leeks, dandelion greens and onions. Other sources include bananas, apples, peas, beans, sweet potatoes, flaxseed, oats, wheat bran, whole wheat and cocoa. Sugar alcohols such as sorbitol, mannitol and xylitol can act as prebiotics as well.

Probiotics are found in cultured yogurt, tempeh, miso, sauerkraut, kimchi, kombucha tea, kefir (both dairy and non-dairy), and non-pasteurized pickled vegetables. There are many different probiotic supplements available. However, there are many different strains and not enough specific research done on each. With that said, a few specific strains of probiotic bacteria, including Lactobacillus and Bifidobacterium, have been shown to be beneficial and effective for overall gut health.

2. Stay hydrated

Staying hydrated is a simple way to support a healthy gut. Water is pulled into the large intestine by fiber to create softer, bulkier stools, allowing things to keep moving along smoothly. Stay hydrated by drinking plenty of water each day and avoid too much soda, sports drinks, punch and other sugar-sweetened beverages.

3. Enjoy meaningful movement

Finding a form of physical activity you enjoy can have a beneficial effect on your gut health. Physical activity helps food move along our digestive tract, leading to more regular bowel movements. Exercise can also help manage symptoms of an irritable bowel, such as constipation and bloating.

4. Reduce stress

This is easier said than done, but taking steps to decrease your stress levels will go a long way in improving your gut health. In an article from the December 2015 issue of Nutrition in Clinical Practice, the Cleveland Clinic's Gail Cresci explains how stress has been linked to irritable bowel symptoms and overall decreased gut health.

Explore and find ways to manage your stress and practice them regularly. Some ideas include meditation, yoga, deep-breathing exercises, exercise, journaling or talking with a good friend.

5. Get enough sleep

Getting seven to nine hours of good-quality sleep each night helps improve mood, cognition and gut health. A 2019 study found that better sleep quality was associated with higher proportions of the gut microbiota.

If you don't get enough quality sleep, start by creating a routine of going to bed and getting up at the same time each day. Putting away cellphones and turning off the TV at least an hour before bedtime can help your body get ready for sleep, too.

Editor's Note: Anything in this article is for informational purposes only. The content is not intended, nor should it be interpreted, to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition; Any opinions, statements, services, offers, or other information or content expressed or made available are those of the respective author(s) or distributor(s) and not of KSL. KSL does not endorse nor is it responsible for the accuracy or reliability of any opinion, information, or statement made in this article. KSL expressly disclaims all liability in respect to actions taken or not taken based on the content of this article.

View original post here:
Gut health: How to improve yours and help fight diabetes - KSL.com

Read More...

100 Years After First Diabetes Breakthrough, Canadian Scientists Believe They’ve Found a Cure – Good News Network

November 22nd, 2020 11:56 am

Scientists at the University of Alberta just cured diabetes in mice, opening the floodgates for research on adapting this cure for humans.

The potential cure is a landmark moment in preventing the growing prevalence of diabetes in our society, a disease which, according to WHO, burdens 422 million people worldwide.

The process involves a stem cell application that reverse-engineers insulin islets out of blood cellsthis cured mice of the disease.

Weve been taking blood samples from patients with diabetes, winding those cells from the blood back in time so that they can be changed, and then were moving them forward in time so that we can turn them into the cells we want, explains the procedures pioneer Dr. James Shapiro to CTV, who famously developed the Edmonton Protocolanother diabetes treatment, in the 1990s.

The Edmonton Protocol involved using islet cells from organ transplants, but required powerful anti-rejection medication. The new stem cell process uses the patients own cells so rejection is impossible.

Like any good scientist, Shapiro wont move beyond the phrase more research is needed, but hopes he can receive support from governments if he can prove the science is the same in humans.

There needs to be preliminary data and ideally a handful of patients that would demonstrate to the world that this is possible and that its safe and effective, said Shapiro.

RELATED: Excited Scientists Make Type-2 Diabetes Breakthrough With First-Ever Glimpse At How Protein Behind Disease Works

The lack of funding has led to a group of volunteers to create a 22 by 22 campaign to raise $22 million by 2022 in order to help advance the procedure so it can be available to humans as soon as possible.

Canada is no stranger to making breakthroughs in diabetes treatmentsSir Frederick Banting had the idea for insulin 100 years ago, with 2022 marking the centennial anniversary of its groundbreaking first use.

SHARE News of This Exciting Breakthrough With Friends

Read more:
100 Years After First Diabetes Breakthrough, Canadian Scientists Believe They've Found a Cure - Good News Network

Read More...

Eluminex Biosciences, an Ophthalmology-Focused Biotechnology CompanyAnnounces Closing of $50 Million Series A Financing – BioSpace

November 20th, 2020 1:57 pm

Shanghai, China, Nov. 20, 2020 Eluminex Biosciences Limited (Eluminex), an ophthalmic biotechnology company committed to the discovery and development of first-in-class and/or best-in-class therapies, today announced the completion of a $50 million (USD) Series A Financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital. The Eluminex headquarters and research and development center are located in Suzhou Industrial Park; the business center is based in Shanghai, and future plans include establishing a global clinical and registration center in the San Francisco Bay Area.

We greatly appreciate the profound level of support and trust from three global investors, said Jinzhong Zhang, PhD, Co-Founder, Chairman, and Chief Executive Officer. With these proceeds, our goal is to build an innovative pipeline addressing critical unmet medical needs in vision-threatening diseases for patients worldwide. Additionally, we are pleased to have three world-renowned professors of ophthalmology as members of our Scientific Advisory Board: Quan Dong Nguyen, MD, MSc (Stanford University), Zuguo Liu, MD, PhD (Xiamen University), and Xiaodong Sun, MD, PhD (Shanghai Jiao Tong University). We are grateful for their significant contributions in helping us develop our pipeline programs.

The company also announced that Charles Semba, MD, has joined Eluminex as Chief Medical Officer (CMO). Dr. Semba is an internationally recognized leader in ophthalmic drug development. He has served as CMO in three prior ophthalmic companies: SARcode Bioscience (acquired by Shire/Takeda), ForSight VISION5 (acquired by Allergan), and Graybug Vision (NASDAQ: GRAY). He has held senior leadership roles as Vice President Ophthalmic Medicine at Shire/Takeda and Ophthalmology Group Head at Genentech. Dr. Semba led the clinical development of ranibizumab (LUCENTIS), the first global blockbuster anti-VEGF agent to reverse blindness in wet age-related macular degeneration and lifitegrast (XIIDRA), the first novel agent for the treatment of both signs and symptoms of dry eye disease; XIIDRA was acquired by Novartis for over $5 billion (USD).

Regarding the success of this financing, all parties have expressed their confidence and expectations for the new company. Closing Series A financing is indeed a major milestone. The leadership at Eluminex should be congratulated for this impressive achievement amidst current global events. commented Dr. Nguyen, Professor of Ophthalmology at the Byers Eye Institute, Stanford University. Such financial success and security demonstrate the trusts that the company has earned from the investment community in Eluminexs research and development therapeutic plans to preserve and enhance vision for patients with devastating ocular diseases worldwide.

Driven by an aging population and overuse of eyes in various ages, the ophthalmic market is seeing huge unmet needs for new products. The teams solid track record and rich experience in ophthalmic drug development enables the company to develop innovative therapies not only for China but for the global market. We are thrilled and honored to join hands with this seasoned team and partner with reputable investors from the very beginning, said Stephen Lin, Partner at Lilly Asia Ventures.

The founding team of Eluminex Biosciences has rich experience in drug development and innovation with great potential in the future. Hillhouse will help Eluminex continue to innovate, research and develop leading ophthalmic disease treatment drugs, meeting the needs of a large number of patients, and continue to create social well-being," said Michael Yi, Partner and Co-Chief Investment Officer of Hillhouse Capital Group.

Quan Capital is committed to foster innovation and bring new solutions to patients with great unmet needs. We are pleased to co-lead the Series A round of Eluminex and are truly impressed by the stellar management team, said Marietta Wu, Managing Director of Quan Capital. We believe this team of seasoned industry veterans both globally and in China will build a leader in ophthalmology with accelerated development of novel therapeutics. Quan looks forward to working closely with the team and contributing our local resources and global networks.

_________________

About Eluminex Biosciences

Eluminex was established in February 2020 with the commitment to leading the development of novel therapeutics for the benefit of patients with vision-threatening eye diseases worldwide. Co-Founders, Dr. Jinzhong Zhang and Dr. Zhenze John Hu, have assembled a top tier management team with significant ophthalmic drug development experience, aiming to build a robust and sustainable innovative ophthalmic pipeline to tackle the unmet clinical needs. For detailed information contact Zhenze John Hu at john.hu@eluminexbio.com

About Lilly Ventures Asia

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Menlo Park. LAVs vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that can treat diseases and improve human health. For more information, visit http://www.lillyasiaventures.com.

Here is the original post:
Eluminex Biosciences, an Ophthalmology-Focused Biotechnology CompanyAnnounces Closing of $50 Million Series A Financing - BioSpace

Read More...

Is BELLUS Health Inc (BLU) the Top Pick in the Biotechnology Industry? – InvestorsObserver

November 20th, 2020 1:57 pm

BELLUS Health Inc (BLU) is around the middle of the Biotechnology industry according to InvestorsObserver. BLU received an overall rating of 43, which means that it scores higher than 43 percent of all stocks. BELLUS Health Inc also achieved a score of 43 in the Biotechnology industry, putting it above 43 percent of Biotechnology stocks. Biotechnology is ranked 36 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

BELLUS Health Inc (BLU) stock is unchanged 0% while the S&P 500 is down -0.27% as of 1:21 PM on Friday, Nov 20. BLU is flat $0.00 from the previous closing price of $3.18 on volume of 1,380,191 shares. Over the past year the S&P 500 has gained 15.10% while BLU is down -53.10%. BLU lost -$0.60 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BELLUS Health Inc (BLU) Stock.

The rest is here:
Is BELLUS Health Inc (BLU) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Kazia Therapeutics Ltd (KZIA) The Right Choice in Biotechnology? – InvestorsObserver

November 20th, 2020 1:57 pm

The 60 rating InvestorsObserver gives to Kazia Therapeutics Ltd (KZIA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, KZIAs 60 overall rating means the stock scores better than 60 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Kazia Therapeutics Ltd (KZIA) stock is trading at $11.12 as of 1:21 PM on Friday, Nov 20, a drop of -$0.88, or -7.33% from the previous closing price of $12.00. The stock has traded between $10.52 and $11.99 so far today. Volume today is 863,594 compared to average volume of 726,043.

Click Here to get the full Stock Score Report on Kazia Therapeutics Ltd (KZIA) Stock.

Link:
Is Kazia Therapeutics Ltd (KZIA) The Right Choice in Biotechnology? - InvestorsObserver

Read More...

Page 293«..1020..292293294295..300310..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick